Publicaciones en las que colabora con Jesús Miguel García-Foncillas López (60)

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2014

  1. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool

    Neuro-Oncology, Vol. 16, Núm. 4, pp. 520-527

2013

  1. KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients

    Oncology Letters, Vol. 6, Núm. 5, pp. 1343-1345

  2. Valoración de marcadores pronósticos de respuesta a bevacizumab en pacientes con cáncer colorrectal avanzado y su utilidad para la individualización del tratamiento

    Anales del sistema sanitario de Navarra, Vol. 36, Núm. 1, pp. 174-177

2012

  1. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

    European Journal of Cancer, Vol. 48, Núm. 12, pp. 1774-1780

  2. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial

    International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593

  3. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array

    World Journal of Gastroenterology, Vol. 18, Núm. 7, pp. 637-645

  4. Identification of predictive circulating biomarkers of bevacizumab- containing regimen efficacy in pre-treated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 107, Núm. 2, pp. 287-290

  5. The multimodal management of locally advanced N2 non-small cell lung cancer: Is there a role for surgical resection? A single institution's experience

    Clinical and Translational Oncology, Vol. 14, Núm. 11, pp. 835-841

2011

  1. A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation

    Oncology Letters, Vol. 2, Núm. 5, pp. 807-809

  2. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

  3. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166

  4. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells

    Stem Cells, Vol. 29, Núm. 11, pp. 1661-1671

  5. Patterns of response after preoperative treatment in gastric cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 80, Núm. 3, pp. 698-704

2010

  1. A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family

    Breast Cancer Research and Treatment, Vol. 121, Núm. 1, pp. 219-220

  2. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  3. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab

    Critical Reviews in Oncology/Hematology, Vol. 74, Núm. 3, pp. 193-202

  4. Selection of extreme phenotypes: The role of clinical observation in translational research

    Clinical and Translational Oncology, Vol. 12, Núm. 3, pp. 174-180

  5. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation

    Molecular Cancer Therapeutics, Vol. 9, Núm. 8, pp. 2265-2275